The ACGT Investigator Award in Cell & Gene Therapy for Solid Tumor Cancers supports translational research projects aimed at advancing next-generation immunotherapies for solid tumors. Funded by the Alliance for Cancer Gene Therapy (ACGT), the programme focuses on innovative cell- and gene-based approaches that have strong potential for clinical translation. Priority areas include CAR-T, TCR, TIL, CAR-NK, CRISPR-based strategies, and synthetic biology platforms. The award is designed to help academic investigators move promising laboratory discoveries toward first-in-human or early clinical development. Collaborative and multidisciplinary approaches are strongly encouraged.
Eligibility Criteria:
Applicants must:
- Hold an MD, PhD, or MD/PhD degree
- Be a tenure-track or tenured independent faculty member
- Conduct translational cell or gene therapy research in solid tumors
- Be affiliated with an academic medical center or research institution
- Conduct the funded research at an institution in the United States or Canada
There are no citizenship restrictions.
Funding Details:
- Total funding: $250,000–$500,000 USD
- Grant term: 2–3 years
- Maximum indirect costs: 10%
- Supports research personnel, supplies, equipment, and translational activities
Deadline:
- Abstract / LOI deadline: 15 May 2026
- Invited full application deadline: 1 September 2026
Where to go for further information:
- RFA details.
- Application portal: ProposalCentral
- Contact: info@acgtfoundation.org